These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3058132)

  • 1. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S; Bellati G; Ideo G
    Minerva Dietol Gastroenterol; 1984; 30(3):255-61. PubMed ID: 6504374
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
    Gorbach HC; Bräuninger HJ
    MMW Munch Med Wochenschr; 1975 Sep; 117(37):1483-6. PubMed ID: 810673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation].
    Denis B; Dimitriou R; Machecourt J; Wolf JE; Page E; Reboud JP
    Arch Mal Coeur Vaiss; 1984 Apr; 77 Spec No():35-40. PubMed ID: 6428361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites.
    Angeli P; Dalla Pria M; De Bei E; Albino G; Caregaro L; Merkel C; Ceolotto G; Gatta A
    Hepatology; 1994 Jan; 19(1):72-9. PubMed ID: 8276370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
    Tosti-Croce C; Mantellini R; Fanti P; Sciarra F
    Minerva Med; 1983 Apr; 74(14-15):791-7. PubMed ID: 6339999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S; Buch J
    Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of K-canrenoate in post-surgical treatment of open heart paediatric surgery (author's transl)].
    Capuani A; Bernabei M; Pasque A; Eufrate S
    G Ital Cardiol; 1980; 10(9):1148-55. PubMed ID: 7461364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone and canrenoate: different antialdosteronic diuretic agents.
    Gentilini P
    Hepatology; 1991 May; 13(5):999-1000. PubMed ID: 2030004
    [No Abstract]   [Full Text] [Related]  

  • 11. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of an aldosterone antagonist in abdominal surgery].
    Ribero F; Remonda G; Morachioli N; Pugnani M
    Ann Osp Maria Vittoria Torino; 1982; 25(1-6):61-70. PubMed ID: 7185311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of diuretics in preventing ascites recurrence.
    Arrigoni A; Andriulli A; Gindro T; Verme G
    Br J Clin Pract; 1988 Mar; 42(3):116-20. PubMed ID: 3207572
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperaldosteronism after heart surgery in children. Part I: Treatment with aldosterone antagonists.
    Haschke F; Wimmer M; Parth K
    Padiatr Padol; 1981; 16(3):317-26. PubMed ID: 7254888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effectiveness of K canrenoate in the treatment of secondary hyperaldosteronism].
    Tartagni F; Pasetti L; Ambrosioni E; Magnani B
    G Clin Med; 1979 Mar; 60(3):196-206. PubMed ID: 520727
    [No Abstract]   [Full Text] [Related]  

  • 17. Lymphocyte function tests in cirrhotic patients under treatment with spironolactone and potassium canrenoate.
    Cuppone R; Del Vecchio S; Zanninelli G; Delle Monache M; Ulissi A; Tavanti A; Angeloni A; Ricci GL
    J Int Med Res; 1988; 16(6):436-42. PubMed ID: 3266156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Controlled clinical study on 2 antialdosterone diuretics in the nephrotic syndrome].
    Russo R; Schena FP; Colombo Pirola L
    Clin Ter; 1984 Apr; 109(1):23-9. PubMed ID: 6233076
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapeutic report on an injectable aldosterone antagonist (K-canrenoate) in states of water-salf retention].
    Coltorti M; Radaeli E; Ciaccio S; Corsini R; Trebbi R
    Clin Ter; 1976 Feb; 76(3):215-34. PubMed ID: 963962
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of hyperaldosteronism].
    Jacobelli A
    Clin Ter; 1984 Jun; 109(6):575-81. PubMed ID: 6236949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.